Latest Angina pectoris Stories
PALO ALTO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that it has entered into an agreement granting exclusive rights to Ranexa(R) (ranolazine prolonged release tablets) in Europe and other countries to the Menarini Group.
By Dr Donohue Q: I am under treatment for angina. When I have an attack of chest pain, I usually can get rid of it with nitroglycerin. My neighbor, exactly my age, has the same thing: coronary artery disease with angina attacks. His doctor is treating him with leg pumps.
By Jane Oppermann At age 70, Jeanne Franz figured she got enough exercise just taking care of her home and keeping up with her 13 grandchildren. But that changed when the Palatine resident had a heart attack two years ago.
PALO ALTO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
Passive smoking kills 7 people per day in Brazil RIO DE JANEIRO, Aug. 22 (Xinhua) -- The diseases caused by passive smoking kills seven people per day, or 2,655 people per year in Brazil, according to a study released Friday by the Rio de Janeiro State University and the Cancer Institute.
Anthera Pharmaceuticals has started the Francis clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an acute coronary syndrome event.
By Annie Freeda Cruez THE journalist was on his way to a nasi lemak breakfast with a colleague when he slumped in the car seat and died. He was just 41. A pulmonary and critical care physician tells ANNIE FREEDA CRUEZ that doctors are seeing more and more young people with coronary heart diseases.
By Pacileo, M Cirillo, P; De Rosa, S; Chiariello, M Dear Editor, We read with great interest the study by Bertz et ai in the last issue of International Angiology, dealing with differences of inflammatory biomarker (i.e.
PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
- To give a box on the ear to.